

Supplementary materials

1. Full search strategy
2. Excluded studies table with reasons
3. Signalling questions for risk of bias assessment

Supplement 1. Full search strategy for all databases run on 08/04/2020

PubMed search

(("COVID-19"[Supplementary Concept] OR "COVID-19"[tiab] OR COVID19[tiab] OR "COVID 19"[tiab] OR "SARS-CoV-2"[tiab] OR "2019-nCoV"[tiab] OR "Novel coronavirus"[tiab] OR "Coronavirus 2019"[tiab] OR "Coronavirus 19"[tiab] OR "COVID 2019"[tiab] OR "2019 ncov"[tiab] OR "Wuhan coronavirus"[tiab])

AND

("Asymptomatic Diseases"[Mesh] OR Asymptomatic[tiab] OR Presymptomatic[tiab] OR "Pre-Symptomatic"[tiab] OR "No symptoms"[tiab] OR "No symptom"[tiab] OR "Silent transmission"[tiab] OR "Silent carrier"[tiab] OR "Silent carriers"[tiab])

AND

(Letter[pt] OR "Epidemiologic Studies"[Mesh] OR "Case-control studies"[Mesh] OR "Cohort Studies"[Mesh] OR "Case control"[tiab] OR Longitudinal[tiab] OR Prospective[tiab] OR Retrospective[tiab] OR "Cross sectional"[tiab] OR "Cross-Sectional Studies"[Mesh] OR Investigated[tiab] OR Analysis[tiab] OR Data[tiab] OR Cases[tiab] OR Ratio[tiab] OR "statistics and numerical data"[sh] OR "epidemiology"[sh])

OR

(("COVID-19"[ti] OR COVID19[ti] OR "COVID 19"[ti] OR "SARS-CoV-2"[ti] OR "2019-nCoV"[ti] OR "Novel coronavirus"[ti] OR "Coronavirus 2019"[ti] OR "Coronavirus 19"[ti] OR "COVID 2019"[ti] OR "2019 ncov"[ti] OR "Wuhan coronavirus"[ti])

AND

(Asymptomatic[ti] OR Presymptomatic[ti] OR "Pre-Symptomatic"[ti])

AND ("2019/01/01"[PDat] : "2020/12/31"[PDat])

Embase search

((COVID-19:ti,ab OR COVID19:ti,ab OR "COVID 19":ti,ab OR SARS-CoV-2:ti,ab OR 2019-nCoV:ti,ab OR "Novel coronavirus":ti,ab OR "Coronavirus 2019":ti,ab OR "Coronavirus 19":ti,ab OR "COVID 2019":ti,ab OR "2019 ncov":ti,ab OR "Wuhan coronavirus":ti,ab)

AND

('asymptomatic disease'/exp OR Asymptomatic:ti,ab OR Presymptomatic:ti,ab OR Pre-Symptomatic:ti,ab OR "No symptoms":ti,ab OR "No symptom":ti,ab OR "Silent transmission":ti,ab OR "Silent carrier":ti,ab OR "Silent carriers":ti,ab)

AND

('letter'/exp OR 'epidemiology'/exp OR 'case control study'/exp OR 'cohort analysis'/exp OR "Case control":ti,ab OR Longitudinal:ti,ab OR Prospective:ti,ab OR Retrospective:ti,ab OR "Cross sectional":ti,ab OR 'cross-sectional study'/exp OR Investigated:ti,ab OR Analysis:ti,ab OR Data:ti,ab OR Cases:ti,ab OR Ratio:ti,ab)

OR

((COVID-19:ti OR COVID19:ti OR "COVID 19":ti OR SARS-CoV-2:ti OR 2019-nCoV:ti OR "Novel coronavirus":ti OR "Coronavirus 2019":ti OR "Coronavirus 19":ti OR "COVID 2019":ti OR "2019 ncov":ti OR "Wuhan coronavirus":ti)

AND

(Asymptomatic:ti OR Presymptomatic:ti OR Pre-Symptomatic:ti)

AND [2019-2020]/py

Cochrane Covid-19 study register

"Asymptomatic Diseases" OR "Viral Load" OR Asymptomatic OR Presymptomatic OR Pre-Symptomatic OR "No symptoms" OR "No symptom" OR "Silent transmission" OR "Silent carrier" OR "Silent carriers"

MedRxiv (pre-print servers) search via Europe PMC

(COVID-19 OR COVID19 OR "COVID 19" OR SARS-CoV-2 OR 2019-nCoV OR "Novel coronavirus" OR "Coronavirus 2019" OR "Coronavirus 19" OR "COVID 2019" OR "2019 ncov" OR "Wuhan coronavirus")

AND

(Asymptomatic OR Presymptomatic OR "No symptoms" OR "No symptom" OR "Silent transmission" OR "Silent carrier" OR "Silent carriers")

Supplement 2. Excluded studies after full text assessment with reasons

#	Reference	Reason for exclusion	Country
1	Zhonghua, L., B. Xing, and Z.Z. Xue, [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. 2020. 41(2): p. 145-151.	No/Unclear follow-up period	China
2	Hu, Z., et al., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. <i>Sci China Life Sci</i> , 2020.	No/Unclear follow-up period	China
3	Liao, J., et al., Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. 2020, medRxiv.	No/Unclear follow-up period	China
4	Ling, Z., et al., Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. <i>Eur J Radiol</i> , 2020. 126: p. 108956.	No/Unclear follow-up period	China
5	Lu, J., et al., A New Features of SARS-CoV-2 Infection in Wenzhou, China. 2020, Research Square.	No/Unclear follow-up period	China
6	Ma, S., et al., Epidemiological parameters of coronavirus disease 2019: a pooled analysis of publicly reported individual data of 1155 cases from seven countries. 2020, medRxiv.	No/Unclear follow-up period	Various
7	Park, S.W., et al., The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak. 2020, medRxiv.	No/Unclear follow-up period	USA
8	Qiu, H., et al., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. <i>Lancet Infect Dis</i> , 2020.	No/Unclear follow-up period	China
9	Shi, H., et al., Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. <i>The Lancet Infectious Diseases</i> , 2020. 20(4): p. 425-434.	No/Unclear follow-up period	China
10	Sun, W.W., et al., [Epidemiological characteristics of 2019 novel coronavirus family clustering in Zhejiang Province]. <i>Zhonghua Yu Fang Yi Xue Za Zhi</i> , 2020. 54(0): p. E027.	No/Unclear follow-up period	China
11	Wang, Y., et al., Clinical Implications of 37 Childhood Cases with 2019-nCoV Infection in Shenzhen, China. 2020, Research Square.	No/Unclear follow-up period	China
12	Chen, J., et al., Clinical progression of patients with COVID-19 in Shanghai, China. <i>Journal of infection</i> , 2020.	No/Unclear follow-up period	China
13	Nakazawa, E., H. Ino, and A. Akabayashi, Chronology of COVID-19 cases on the Diamond Princess cruise ship and ethical considerations: a report from Japan. <i>Disaster Med Public Health Prep</i> , 2020: p. 1-27.	No/Unclear follow-up period	Japan
14	Su, L., et al., The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. <i>Emerg Microbes Infect</i> , 2020. 9(1): p. 707-713.	No/Unclear follow-up period	China
15	Xu, Y., et al., Clinical Characteristics of SARS-CoV-2 Pneumonia Compared to Controls in Chinese Han Population. 2020, medRxiv.	No/Unclear follow-up period	China
16	Zhang, J., et al., Epidemiological and clinical characteristics of imported cases with COVID-19 infection: a multicentre study. 2020, Research Square.	No/Unclear follow-up period	China
17	Gudbjartsson, D.F., et al., Spread of SARS-CoV-2 in the Icelandic Population. <i>N Engl J Med</i> , 2020.	No/Unclear follow-up period	Iceland
18	Sutton, D., et al., Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. <i>New England Journal of Medicine</i> , 2020.	No/Unclear follow-up period	USA
19	Dong Y, et al. Epidemiology of COVID-19 among children in China. <i>Pediatrics</i> . 2020;145(6):e20200702	No/Unclear follow-up period	China
20	Corman, V., et al., SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. 2020, medRxiv.	Unclear sampling frame	Germany
21	Day, M., Covid-19: four fifths of cases are asymptomatic, China figures indicate. <i>Bmj</i> , 2020. 369: p. m1375.	Unclear sampling frame	China
22	Day, M., Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. <i>Bmj</i> , 2020. 368: p. m1165.	Unclear sampling frame	Italy
23	Mizumoto, K., et al., Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. <i>Euro Surveill</i> , 2020. 25(10).	Unclear sampling frame	Japan
24	Qiu, C., et al., Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China. 2020, medRxiv.	Unclear sampling frame	China
25	Tao, Y., et al., High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China. 2020, medRxiv.	Unclear sampling frame	China
26	Tian, S., et al., Characteristics of COVID-19 infection in Beijing. <i>J Infect</i> , 2020. 80(4): p. 401-406.	Unclear sampling frame	China
27	Zhang, Z., et al., Clinical characteristics of COVID-19 in children compared with adults in Shandong, China. 2020, Research Square.	Unclear sampling frame	China
28	Feng, K., et al., [Analysis of CT features of 15 children with 2019 novel coronavirus infection]. <i>Zhonghua Er Ke Za Zhi</i> , 2020. 58(4): p. 275-278.	Unclear sampling frame	China
29	Nishiura H, Kobayashi T, Suzuki A, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). <i>International Journal of Infectious Diseases</i> 2020.	Unclear sampling frame	Japan
30	Lytras T, Dellis G, Flountzi A, et al. High prevalence of SARS-CoV-2 infection in repatriation flights to Greece from three European countries. <i>Journal of Travel Medicine</i> 2020.	Unclear sampling frame	Greece
31	Zhou, X., et al., Follow-up of the asymptomatic patients with SARS-CoV-2 infection. <i>Clin Microbiol Infect</i> , 2020.	Unclear sampling frame	China
32	Rothe C., et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany	No asymptomatic data (pre-symptomatic)	Germany
33	COVID-19 National Emergency Response Center, E.a.C.M.T., Korea Centers for Disease Control and Prevention., Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. <i>Osong Public Health Res Perspect</i> , 2020. 11(1): p. 8-14.	No asymptomatic data	Korea

34	Du, Z., et al., Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. <i>Emerg Infect Dis</i> , 2020. 26(6).	No asymptomatic data	China
35	Ghinai, I., et al., First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. <i>Lancet</i> , 2020. 395(10230): p. 1137-1144.	No asymptomatic data	USA
36	Ping, K., Epidemiologic Characteristics of COVID-19 in Guizhou, China. 2020, medRxiv.	No asymptomatic data	China
37	Scott, S.E., et al., First Mildly Ill, Non-Hospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States - Maricopa County, Arizona, 2020. <i>Clin Infect Dis</i> , 2020.	No asymptomatic data	USA
38	Qian, G., et al., A COVID-19 Transmission within a family cluster by presymptomatic infectors in China. <i>Clin Infect Dis</i> , 2020.	No asymptomatic data	China
39	Gautret, P., et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. <i>Int J Antimicrob Agents</i> , 2020: p. 105949.	Asymptomatic results reported with sx	France
40	Wei, W. Report, Presymptomatic Transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. 2020. 69.	No asymptomatic data	Singapore
41	Liu, Y., S. Funk, and S. Flasche, The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019. 2020. 5(58): p. 58.	No asymptomatic data	China
42	Kim, E.S., et al., Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. <i>J Korean Med Sci</i> , 2020. 35(13): p. e142.	Insufficient asymptomatic results	Korea
43	Roxby, A et al. Report, Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults—Seattle, Washington, 2020. 2020. 69.	Insufficient asymptomatic results	USA
44	Bai, Y., et al., Presumed Asymptomatic Carrier Transmission of COVID-19. <i>Jama</i> , 2020.	Small cluster, only 1 index case	China
45	Ki, M., Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. <i>Epidemiol Health</i> , 2020. 42: p. e2020007.	Small cluster, only 1 index case	Korea
46	Le, T.Q.M., et al., Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers, Vietnam, 2020. <i>Emerg Infect Dis</i> , 2020. 26(7).	Small cluster	Vietnam
47	Zhao, D., et al., Clinical characteristics of 10 children with COVID-19 outside of Wuhan in Hubei Province. 2020, Research Square.	Small cluster	China
48	Pan, X., et al., Asymptomatic cases in a family cluster with SARS-CoV-2 infection. <i>The Lancet Infectious Diseases</i> , 2020. 20(4): p. 410-41.1	Small cluster	China
49	Aguilar, J., et al., Investigating the Impact of Asymptomatic Carriers on COVID-19 Transmission. 2020, medRxiv.	Modelling study	Various
50	Aleta, A. and Y. Moreno, Evaluation of the potential incidence of COVID-19 and effectiveness of contention measures in Spain: a data-driven approach. 2020, medRxiv.	Modelling study	Spain
51	Jing, Q., et al., Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. 2020, medRxiv.	Modelling study	China
52	Stock, J.H., et al., Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland. medRxiv, 2020: p. 2020.04.06.20055582.	Modelling study	Iceland
53	Centre Hospitalier Intercommunal, C., Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children. <i>ClinicalTrials.gov</i> , 2020.	Trial protocol, no data	France
54	Centre Hospitalier Intercommunal, C., Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children. <i>ClinicalTrials.gov</i> , 2020.	Trial protocol, no data	France
55	HaEmek Medical Center, I., Chloroquine for Mild Symptomatic and Asymptomatic COVID-19. <i>ClinicalTrials.gov</i> , 2020.	Trial protocol, no data	Israel
56	de Souza, T.H., et al., Clinical Manifestations of Children with COVID-19: a Systematic Review. 2020, medRxiv.	Review	Various
57	Mullins, E., et al., Coronavirus in pregnancy and delivery: rapid review. <i>Ultrasound Obstet Gynecol</i> , 2020.	Rapid review of case studies	Various
58	Song, H., et al., A considerable proportion of individuals with asymptomatic SARS-CoV-2 infection in Tibetan population. 2020, medRxiv.	No contact tracing & Asymptomatic on antiviral Rx	Tibet
59	Wang, D., et al., [Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China]. <i>Zhonghua Er Ke Za Zhi</i> , 2020. 58(4): p. E011.	No contact tracing & Asymptomatic on antiviral Rx	China
60	Al-Tawfiq, J.A., Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). <i>Travel Med Infect Dis</i> , 2020: p. 101608.	MERS-CoV, no COVID-19	Various
61	Shaman, J. and M. Galanti, Direct Measurement of Rates of Asymptomatic Infection and Clinical Care-Seeking for Seasonal Coronavirus. 2020, medRxiv.	Flu 2018, no COVID-19	USA
62	Hu, Z.B. and C. Ci, [Screening and management of asymptomatic infection of corona virus disease 2019 (COVID-19)]. <i>Zhonghua Yu Fang Yi Xue Za Zhi</i> , 2020. 54(0): p. E025.	No primary data	China
63	Dipesh Navsaria, M. and M. MSLIS, Epidemiology of Pediatric Patients With COVID-19 in China	No primary data	China
64	Wang, X.F., et al., [Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]. <i>Zhonghua Er Ke Za Zhi</i> , 2020. 58(0): p. E008.	Retracted	China

Supplement 3. Risk of bias assessment signalling questions

1. Was the sampling frame a true or close representation of the target population (all at risk of SARS-CoV-2 infection)?
 - 1a. What method of sampling was used? Complete sampling (census), Random selection, Other?
 - 1b. Is there likely to be bias from selection of a study population that doesn't match the target population (all at risk of the infection)?
2. Was there incomplete ascertainment of infection status in the study population?
 - 2a. Was a reference standard applied to everyone (or a random sample) of the study population? Is the probability of having a reference standard applied different for people without symptoms/mild symptoms/with severe symptoms?
 - 2b. Is there likely to be bias from incomplete ascertainment of infection status in the study population?
3. Were acceptable methods used to identify individuals in the study population who had SARS-CoV-2 infection (denominator for research question)?
 - 3a. What reference standards were used to determine SARS-CoV-2 infection status, and what is the estimated diagnostic accuracy for these? Did the choice of reference standard differ depending on whether or not symptoms were present, and the severity of symptoms?
 - 3b. Is there likely to be bias from differential application of reference standards to define infection status
4. Was an acceptable case definition used in the study (numerator for the research question)?
 - 4a. What was the definition of asymptomatic infection? Was there distinction between asymptomatic and minimally symptomatic?
 - 4b. Is there likely to be bias from the definition of asymptomatic infection?
5. Was the length of follow-up to define case definition (asymptomatic infection) appropriate?
 - 5a. Was the follow-up of people without symptoms sufficient to allow for the incubation period, to allow classification as asymptomatic vs pre-symptomatic?
 - 5b. Is there likely to be bias from insufficient follow-up?